Adverse renal effects of hydrochlorothiazide in rats with myocardial infarction treated with an ACE inhibitor

European Journal of Pharmacology

Volumn 602, Issue 2-3, 2009, Pages 373-379

  Westendorp, Bart ^a   Hamming, Inge ^a   Szymanski, Mariusz K ^a   Navis, Gerjan ^a   van Goor, Harry ^a   Buikema, Hendrik ^a   van Gilst, Wiek H ^a   Schoemaker, Regien G ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

ACE inhibitor; Hydrochlorotiazide; Myocardial infarction; Renal dysfunction

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROCHLOROTHIAZIDE; QUINAPRIL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; HEART FUNCTION; HEART INFARCTION; KIDNEY DISEASE; KIDNEY FIBROSIS; KIDNEY INJURY; KIDNEY STRUCTURE; MALE; MYOFIBROBLAST; NONHUMAN; PRIORITY JOURNAL; RAT; SURVIVAL;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; BIOLOGICAL MARKERS; DIURETICS; HEART; HYDROCHLOROTHIAZIDE; KIDNEY; MALE; MYOCARDIAL INFARCTION; PROGNOSIS; RATS; RATS, SPRAGUE-DAWLEY; SURVIVAL RATE; TIME FACTORS;

EID: 58149171776     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2008.11.055     Document Type: Article

References (29)

1. Amann K., Wiest G., Zimmer G., Gretz N., Ritz E., and Mall G. Reduced capillary density in the myocardium of uremic rats - a stereological study. Kidney Int. 42 (1992) 1079-1085
2. Amann K., Tyralla K., Gross M.L., Schwarz U., Tornig J., Haas C.S., Ritz E., and Mall G. Cardiomyocyte loss in experimental renal failure: prevention by ramipril. Kidney Int. 63 (2003) 1708-1713
3. Bucher J.R., Huff J., Haseman J.K., Eustis S.L., Elwell M.R., Davis Jr. W.E., and Meierhenry E.F. Toxicology and carcinogenicity studies of diuretics in F344 rats and B6C3F1 mice. 1. Hydrochlorothiazide. J. Appl. Toxicol. 10 (1990) 359-367
4. Buter H., Hemmelder M.H., Navis G., de Jong P.E., and de Zeeuw D. The blunting of the antiproteinuric efficacy of ACE inhibition by high sodium intake can be restored by hydrochlorothiazide. Nephrol. Dial. Transplant. 13 (1998) 1682-1685
5. Chuen M.J., and MacFadyen R.J. Dose-dependent association between use of loop diuretics and mortality in advanced systolic heart failure. Am. J. Cardiol. 98 (2006) 1416-1417
6. Dikow R., Kihm L.P., Zeier M., Kapitza J., Tornig J., Amann K., Tiefenbacher C., and Ritz E. Increased infarct size in uremic rats: reduced ischemia tolerance?. J. Am. Soc. Nephrol. 15 (2004) 1530-1536
7. Eshaghian S., Horwich T.B., and Fonarow G.C. Relation of loop diuretic dose to mortality in advanced heart failure. Am. J. Cardiol. 97 (2006) 1759-1764
8. Esnault V.L., Ekhlas A., Delcroix C., Moutel M.G., and Nguyen J.M. Diuretic and enhanced sodium restriction results in improved antiproteinuric response to RAS blocking agents. J. Am. Soc. Nephrol. 16 (2005) 474-481
9. Gibson C.M., Pinto D.S., Murphy S.A., Morrow D.A., Hobbach H.P., Wiviott S.D., Giugliano R.P., Cannon C.P., Antman E.M., and Braunwald E. Association of creatinine and creatinine clearance on presentation in acute myocardial infarction with subsequent mortality. J. Am. Coll. Cardiol. 42 (2003) 1535-1543
10. Hamming I., Navis G., Kocks M.J., and van Goor H. ACE inhibition has adverse renal effects during dietary sodium restriction in proteinuric and healthy rats. J. Pathol. 209 (2006) 129-139
11. Heeg J.E., de Jong P.E., van der Hem G.K., and de Zeeuw D. Efficacy and variability of the antiproteinuric effect of ACE inhibition by lisinopril. Kidney Int. 36 (1989) 272-279
12. Kohzuki M., Kanazawa M., Yoshida K., Tsutsumi E., Yasujima M., Abe K., Johnston C.I., and Sato T. Cardiomegaly and vasoactive hormones in rats with chronic myocardial infarction: long-term effects of chlorothiazide. Clin. Sci. (Lond) 90 (1996) 31-36
13. Lijinsky W., and Reuber M.D. Pathologic effects of chronic administration of hydrochlorothiazide, with and without sodium nitrite, to F344 rats. Toxicol. Ind. Health 3 (1987) 413-422
14. Loffing J., Loffing-Cueni D., Hegyi I., Kaplan M.R., Hebert S.C., Le Hir M., and Kaissling B. Thiazide treatment of rats provokes apoptosis in distal tubule cells. Kidney Int. 50 (1996) 1180-1190
15. MacDonald J.R., Susick Jr. R.L., Pegg D.G., and Dominick M.A. Renal structure and function in rats after suprapharmacologic doses of quinapril, an angiotensin-converting enzyme inhibitor. J. Cardiovasc. Pharmacol. 19 (1992) 282-289
16. Navis G., de Jong P., Donker A.J., van der Hem G.K., and de Zeeuw D. Diuretic effects of angiotensin-converting enzyme inhibition: comparison of low and liberal sodium diet in hypertensive patients. J. Cardiovasc. Pharmacol. 9 (1987) 743-748
17. Ogata S., Sharyo S., Hinman D.J., and Manabe S. Renal effects of 26-week administration of olmesartan medoxomil/hydrochlorothiazide in rats. J. Toxicol. Sci. 29 (2004) 37-46
18. Pinto Y.M., de Smet B.G., van Gilst W.H., Scholtens E., Monnink S., de Graeff P.A., and Wesseling H. Selective and time related activation of the cardiac renin-angiotensin system after experimental heart failure: relation to ventricular function and morphology. Cardiovasc. Res. 27 (1993) 1933-1938
19. Pinto Y.M., van Geel P.P., Alkfaji H., van Veldhuisen D.J., and van Gilst W.H. Dosing of ACE inhibitors in left ventricular dysfunction: does current clinical dosing provide optimal benefit?. J. Cardiovasc. Pharmacol. 34 Suppl 1 (1999) S13-S17
20. Riemenschneider T., and Bohle A. Morphologic aspects of low-potassium and low-sodium nephropathy. Clin. Nephrol. 19 (1983) 271-279
21. Rigsby C.S., Cannady W.E., and Dorrance A.M. Aldosterone: good guy or bad guy in cerebrovascular disease?. Trends Endocrinol. Metab. 16 (2005) 401-406
22. Sarnak M.J., Levey A.S., Schoolwerth A.C., Coresh J., Culleton B., Hamm L.L., McCullough P.A., Kasiske B.L., Kelepouris E., Klag M.J., Parfrey P., Pfeffer M., Raij L., Spinosa D.J., and Wilson P.W. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation 108 (2003) 2154-2169
23. Schaison F.H., Fernando Ramirez-Gil J., Ciferri S., Bernard M., Baudin B., Mougenot N., Carayon A., and Lechat P. Acute and long-term dose-response study of quinapril on hormonal profile and tissue angiotensin-converting enzyme in Wistar rats. J. Cardiovasc. Pharmacol. 28 (1996) 11-18
24. Sorensen C.R., Brendorp B., Rask-Madsen C., Kober L., Kjoller E., and Torp-Pedersen C. The prognostic importance of creatinine clearance after acute myocardial infarction. Eur. Heart J. 23 (2002) 948-952
25. Tokmakova M.P., Skali H., Kenchaiah S., Braunwald E., Rouleau J.L., Packer M., Chertow G.M., Moye L.A., Pfeffer M.A., and Solomon S.D. Chronic kidney disease, cardiovascular risk, and response to angiotensin-converting enzyme inhibition after myocardial infarction: the Survival And Ventricular Enlargement (SAVE) study. Circulation 110 (2004) 3667-3673
26. van Veldhuisen D.J., Genth-Zotz S., Brouwer J., Boomsma F., Netzer T., Man In 'T Veld A.J., Pinto Y.M., Lie K.I., and Crijns H.J. High- versus low-dose ACE inhibition in chronic heart failure: a double-blind, placebo-controlled study of imidapril. J. Am. Coll. Cardiol. 32 (1998) 1811-1818
27. Vogt L., Waanders F., Boomsma F., de Zeeuw D., and Navis G. Effects of dietary sodium and hydrochlorothiazide on the antiproteinuric efficacy of losartan. J. Am. Soc. Nephrol. 19 (2008) 999-1007
28. Westendorp B., Schoemaker R.G., Buikema H., de Zeeuw D., Boomsma F., van Gilst W.H., and van Veldhuisen D.J. Beneficial effects of add-on hydrochlorothiazide in rats with myocardial infarction optimally treated with quinapril. Eur. J. Heart Fail. 7 (2005) 1085-1094
29. Westendorp B., Schoemaker R.G., van Gilst W.H., van Veldhuisen D.J., and Buikema H. Hydrochlorothiazide increases plasma or tissue angiotensin-converting enzyme-inhibitor drug levels in rats with myocardial infarction: differential effects on lisinopril and zofenopril. Eur. J. Pharmacol. 527 (2005) 141-149